Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANI PHARMACEUTICALS INCANIP · Entity 4638 | Director | May 23, 2023 | May 24, 2023 |
| Spindletop Health Acquisition Corp.SCHAU · Entity 133576 | Director | November 03, 2021 | November 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANI PHARMACEUTICALS INC
Report date May 23, 2023 · Filed May 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,561 |
Reported balance
After 2023-05-23 transaction · row 1
1 source rowRow 1 · 2023-05-23 · Grant · Acquired 6,865 · Balance 38,561 F1: Represents a restricted stock award that will vest in full on May 23, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock award that will vest in full on May 23, 2024.
Spindletop Health Acquisition Corp.
Report date November 03, 2021 · Filed November 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-11-03 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the Issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-254531), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the Issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-254531), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HUMANA INC
Report date April 18, 2019 · Filed April 19, 2019
Section 16 reporting ended · disclosed 2019-04-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Humana CommonSEC Table I · non-derivative | Direct | 118 |
Reported balance
Holding disclosure · report date 2019-04-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 118 |
| Stock UnitSEC Table II · derivative / convertible security | Direct | 21,075 |
Reported balance
Holding disclosure · report date 2019-04-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 21,075 F1: Annual Director's fee payable in stock units which have been deferred at the election of the reporting person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1) and the total includes the vested portion that was subsequently deferred for years 2013 and later. |
| Stock UnitSEC Table II · derivative / convertible security | Direct | 594 |
Reported balance
Holding disclosure · report date 2019-04-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 594 F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 588 |
Reported balance
Holding disclosure · report date 2019-04-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 588 F3: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual Director's fee payable in stock units which have been deferred at the election of the reporting person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1) and the total includes the vested portion that was subsequently deferred for years 2013 and later.
F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).
F3: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2023 Filed May 24, 2023 20:31 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 6,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064146 · tm2316872-2_4seq1.xml · nonDerivative · entry 1 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,561 F1 · kind: Represents a restricted stock award that will vest in full on May 23, 2024. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 22:28 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 10,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004398 · form4-04292022_030424.xml · nonDerivative · entry 1 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,696 F1 · kind: Represents a restricted stock award that will vest in full on April 27, 2023. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:38 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 9,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-001656 · form4-03252021_010359.xml · nonDerivative · entry 1 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,647 F1 · kind: Represents a restricted stock award that will vest in full on March 23, 2022. Read SEC document |
| April 10, 2020 Filed Apr 14, 2020 20:33 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 7,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-046396 · tm2015775d5_form4.xml · nonDerivative · entry 1 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,355 F1 · kind: The restricted stock vests on April 10, 2021. Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:00 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | PurchaseCommon Stock | 1,445 | $68.76 | $99,358.20 |
DisclosureSEC source: 0001144204-19-028634 · tv522581_form4.xml · nonDerivative · entry 1 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,236 F1 · price: The shares were acquired in multiple trades at prices ranging from $68.70 to $68.78. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Options · Derivative | 2,409 | $0.00 Strike: $66.39 | $0.00 |
DisclosureSEC source: 0001144204-19-017413 · tv517662_4.xml · derivative · entry 2 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,409 Underlying: Common Stock · 2,409 shares Expires 2029-03-27 F1 · security: The restricted stock and stock option vest on March 28, 2020. F1 · derivative.exercise_date: The restricted stock and stock option vest on March 28, 2020. Read SEC document |
| March 28, 2019 Filed Apr 1, 2019 20:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 1,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-017413 · tv517662_4.xml · nonDerivative · entry 1 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,791 F1 · security: The restricted stock and stock option vest on March 28, 2020. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:29 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-19-000003 · edgar.xml · derivative · entry 4 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588 Underlying: Humana Common · 588 shares Expires not disclosed F3 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2019. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:29 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 90 | $284.57 | $25,610.85 |
DisclosureSEC source: 0000049071-19-000003 · edgar.xml · derivative · entry 3 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 594 Underlying: Humana Common · 90 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantStock Options · Derivative | 2,225 | $0.00 Strike: $65.86 | $0.00 |
DisclosureSEC source: 0001144204-18-033530 · tv496175_4.xml · derivative · entry 2 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,225 Underlying: Common Stock · 2,225 shares Expires 2028-06-05 F1 · security: The restricted stock and stock options are subject to vesting, and 50% of the restricted stock and stock options vest on May 17, 2019, and the remaining 50% of the restricted stock and stock options vest on May 17, 2020. F1 · derivative.exercise_date: The restricted stock and stock options are subject to vesting, and 50% of the restricted stock and stock options vest on May 17, 2019, and the remaining 50% of the restricted stock and stock options vest on May 17, 2020. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 20:02 UTC | ANI PHARMACEUTICALS INC ANIP · Entity 4638 | GrantCommon Stock | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-033530 · tv496175_4.xml · nonDerivative · entry 1 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 F1 · security: The restricted stock and stock options are subject to vesting, and 50% of the restricted stock and stock options vest on May 17, 2019, and the remaining 50% of the restricted stock and stock options vest on May 17, 2020. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 20:55 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000003 · edgar.xml · derivative · entry 4 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658 Underlying: Humana Common · 658 shares Expires not disclosed F3 · security: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2018. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2018. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2018. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2018. Read SEC document |
| December 31, 2017 Filed Jan 3, 2018 20:55 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 84 | $249.45 | $20,953.80 |
DisclosureSEC source: 0000049071-18-000003 · edgar.xml · derivative · entry 3 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504 Underlying: Humana Common · 84 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:31 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 761 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-17-000004 · edgar.xml · derivative · entry 4 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 761 Underlying: Humana Common · 761 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2017. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2017. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan. 100% of the award is vesting on 12/31/2017. Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 21:31 UTC | HUMANA INC HUM · Entity 1429 | GrantStock Unit · Derivative | 71 | $203.53 | $14,450.63 |
DisclosureSEC source: 0000049071-17-000004 · edgar.xml · derivative · entry 3 NASH DAVID · CIK 0001251968 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420 Underlying: Humana Common · 71 shares Expires not disclosed F2 · security: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_price: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.exercise_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). F2 · derivative.expiration_date: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until his resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.